FLC Video Highlights Partnership Resulting in Commercialization of axicabtagene ciloleucel

The Success of Partnerships

Dr. Steven Rosenberg shares the story of the development and commercialization of axicabtagene ciloleucel, a highly personalized CAR T-cell immunotherapy for the treatment of cancer. Watch the video.

A new video produced by the Federal Laboratory Consortium (FLC) as part of their Labs in Action series highlights a successful NCI partnership to develop and commercialize axicabtagene ciloleucel, a highly personalized CAR T-cell immunotherapy for the treatment of cancer.

FLC Highlights a Successful NCI Collaboration

Axicabtagene ciloleucel was developed by Steven Rosenberg, M.D., Ph.D. (chief, Surgery Branch, Center for Cancer Research, NCI) and his colleagues. It was approved by the FDA on October 18, 2017, for patients with large-B-cell lymphomas whose cancer has progressed after receiving at least two prior treatment regimens.

The technology was licensed to Kite Pharma, Inc., now a Gilead Company, as part of a broader research agreement for further development and commercialization after promising early-phase clinical trials conducted at NCI. “The technology transfer office has been vital to our ability to move from the laboratory into widespread clinical application,” commented Dr. Rosenberg. The video also features the technology transfer perspective of the TTC technology transfer managers involved.

Watch the video produced by the FLC to learn more about the partnership and development of axicabtagene ciloleucel, distributed by Kite as Yescarta®.